Immunopathogenesis associated with formaldehyde-inactivated RSV vaccine in preclinical and clinical studies

被引:25
|
作者
Muralidharan, Abenaya [1 ,2 ,5 ]
Li, Changgui [3 ,4 ]
Wang, Lisheng [5 ]
Li, Xuguang [1 ,2 ,5 ]
机构
[1] Hlth Canada, Ctr Biol Evaluat, Biol & Genet Therapies Directorate, Ottawa, ON, Canada
[2] WHO Collaborating Ctr Standardizat & Evaluat Biol, Ottawa, ON, Canada
[3] Natl Inst Food & Drug Control, Dept Viral Vaccine 3, Beijing, Peoples R China
[4] WHO Collaborating Ctr Standardizat & Evaluat Biol, Beijing, Peoples R China
[5] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada
关键词
Formaldehyde-inactivated vaccine; RSV; animal models; vaccine enhanced disease; immunopathogenesis; RESPIRATORY SYNCYTIAL VIRUS; MONOPHOSPHORYL-LIPID-A; IMMUNIZED BALB/C MICE; CD8; T-CELLS; G-GLYCOPROTEIN; PULMONARY EOSINOPHILIA; MURINE MODEL; COTTON RATS; LAMB MODEL; DISEASE;
D O I
10.1080/14760584.2017.1260452
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: Respiratory syncytial virus (RSV) infection is responsible for one-third of deaths of acute lower respiratory infection in children less than one-year-old. The formaldehyde-inactivated RSV vaccine trial conducted in the 1960s predisposed the vaccinees to more serious RSV infection instead of protection. Better understanding of the underlying mechanism is of critical importance for better designing of safe and effective RSV vaccines.Areas covered: PubMed was searched to review immunopathology induced by RSV vaccines. We intend to dissect the differences in clinical and pathological manifestations of enhanced respiratory disease (ERD) in different animal models in comparison with humans. Formaldehyde-inactivated RSV vaccine causes ERD in both humans and animals, while RSV vaccine without formaldehyde treatment could also induce similar disease in animals, suggesting multiple pathways may be involved.Expert commentary: Identification of biomarkers pertinent to clinical evaluation should be further explored for safety assessment of RSV vaccines in human trials.
引用
收藏
页码:351 / 360
页数:10
相关论文
共 50 条
  • [1] COMPLEMENT FIXATION REACTION FOR MEASUREMENT OF IMMUNOGENIC ANTIGENS IN FORMALDEHYDE-INACTIVATED POLIOMYELITIS VACCINE
    MACMORIN.HG
    WARDLAW, AC
    WEBER, JCW
    JOURNAL OF IMMUNOLOGY, 1965, 94 (04): : 611 - &
  • [2] Formaldehyde-inactivated human enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine
    Chen, Chun-Wei
    Lee, Yi-Ping
    Wang, Ya-Fang
    Yu, Chun-Keung
    VACCINE, 2011, 29 (15) : 2772 - 2776
  • [3] Formaldehyde-Inactivated Whole-Virus Vaccine Protects a Murine Model of Enterovirus 71 Encephalomyelitis against Disease
    Ong, Kien Chai
    Devi, Shamala
    Cardosa, Mary Jane
    Wong, Kum Thong
    JOURNAL OF VIROLOGY, 2010, 84 (01) : 661 - 665
  • [4] A randomised controlled trial of the immunogenicity and safety of a formaldehyde-inactivated Coxiella burnetii vaccine in 8-week-old goats
    Muleme, Michael
    Devlin, Joanne M.
    Campbell, Angus
    Vincent, Gemma
    Benham, Paul John
    Sprohnle, Cleide
    Stent, Andrew
    Cameron, Alexander
    Islam, Aminul
    Graves, Stephen
    Wilks, Colin
    Stenos, John
    Firestone, Simon M.
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2021, 236
  • [5] The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans
    Kistner, Otfried
    Barrett, Noel
    Bruehmann, Axel
    Reiter, Manfred
    Mundt, Wolfgang
    Savidis-Dacho, Helga
    Schober-Bendixen, Susanne
    Dorner, Friedrich
    Aaskov, John
    VACCINE, 2007, 25 (25) : 4845 - 4852
  • [6] Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies
    Kandeil, Ahmed
    Mostafa, Ahmed
    Hegazy, Rehab R.
    El-Shesheny, Rabeh
    El Taweel, Ahmed
    Gomaa, Mokhtar R.
    Shehata, Mahmoud
    Elbaset, Marawan A.
    Kayed, Ahmed E.
    Mahmoud, Sara H.
    Moatasim, Yassmin
    Kutkat, Omnia
    Yassen, Noha N.
    Shabana, Marwa E.
    GabAllah, Mohamed
    Kamel, Mina Nabil
    Abo Shama, Noura M.
    El Sayes, Mohamed
    Ahmed, Amira N.
    Elalfy, Zahraa S.
    Mohamed, Bassim M. S. A.
    Abd El-Fattah, Safa N.
    El Hariri, Hazem Mohamed
    Abdel Kader, Mona
    Azmy, Osama
    Kayali, Ghazi
    Ali, Mohamed A.
    VACCINES, 2021, 9 (03) : 1 - 15
  • [7] ALTERED REACTIVITY TO RESPIRATORY SYNCYTIAL VIRUS - ANTIBODY RESPONSE TO RSV ANTIGENS AND STUDIES OF PATHOGENESIS OF ATYPICAL RSV ILLNESS IN RECIPIENTS OF INACTIVATED VACCINE
    ELLER, JJ
    FULGINIT.VA
    ROBINSON, AA
    NAGAHAMA, H
    SHIRA, J
    PLUNKET, DC
    PEDIATRIC RESEARCH, 1971, 5 (08) : 380 - &
  • [8] Pre-Clinical Studies of Inactivated Polyvalent HFRS Vaccine
    Dzagurova, Tamara K.
    Siniugina, Alexandra A.
    Ishmukhametov, Aidar A.
    Egorova, Maria S.
    Kurashova, Svetlana S.
    Balovneva, Maria, V
    Deviatkin, Andrey A.
    Tkachenko, Petr E.
    Leonovich, Oksana A.
    Tkachenko, Evgeny A.
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2020, 10
  • [9] THE CUTTER INCIDENT - POLIOMYELITIS FOLLOWING FORMALDEHYDE-INACTIVATED POLIOVIRUS VACCINATION IN THE UNITED-STATES DURING THE SPRING OF 1955 .2. RELATIONSHIP OF POLIOMYELITIS TO CUTTER VACCINE
    NATHANSON, N
    LANGMUIR, AD
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 1995, 142 (02) : 109 - 140
  • [10] Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults
    Nussbaum, Jesse
    Cao, Xin
    Railkar, Radha A.
    Sachs, Jeffrey R.
    Spellman, Daniel S.
    Luk, Julie
    Shaw, Christine A.
    Cejas, Pedro J.
    Citron, Michael P.
    Al -Ibrahim, Mohamed
    Han, David
    Pagnussat, Sandra
    Stoch, S. Aubrey
    Lai, Eseng
    Bett, Andrew J.
    Espeseth, Amy S.
    VACCINE, 2023, 41 (44) : 6488 - 6501